Advertisement

Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81
Organisation › Details

PRECIOUS project (2) (scaling-up immunomodulating nanomedicines for multimodal precision cancer immunotherapy) (EU, FP8, 201605–202104)

The consortium consists of academic experts in the field from 5 leading institutes (RadboudUMC, University of Konstanz, Institute of Macromolecular Chemistry ASCR, University of Oxford and Fondazione IRCCS Istituto Nazionale dei Tumori) with outstanding track records in the fields of immunotherapy, tumour immunology, preclinical drug development and clinical trials. In addition, it includes cutting-edge biotech companies that will enable project results to be translated to the clinic. Evonik Nutrition & Care GmbH is the lead manufacturer of PLGA-based particles and will bring in invaluable expertise on manufacturing of nanomedicines. iTeos Therapeutics will develop and provide novel immunomodulators that target the tumour micro-environment. iOx Therapeutics and Oncoarendi Therapeutics will contribute their promising, novel immunomodulators (iNKT and ARG inhibitors respectively) to be part of the immunomodulating nanomedicine platform. SMS-oncology will support the clinical development path with their broad knowledge on clinical trial design and implementation. ttopstart, involved in developing the business cases of many leading cancer therapies and diagnostic tests, will be responsible for the business aspects of PRECIOUS by ensuring a strong exploitation strategy and tight project management. The combined expertise will allow the PRECIOUS consortium to truly perform translational research towards benefit of the most important stakeholder, cancer patients in need of novel treatment strategies. The project will kick off in May 2016 and has a duration of 60 months. *

 

Period Start 2016-05-01 start
Period End 2021-04-30 end
Products Industry cancer immunotherapy (immuno-oncology, I-O)
  Industry 2 nanomedicine
     
  City n. a. 
    Address record changed: 2016-04-29
     
Basic data Employees n. a.
     
    * Document for �About Section�: iTeos Therapeutics S.A.. (4/21/16). "Press Release: €8.3 Million EU Grant Awarded to International »PRECIOUS« Consortium to Integrate Nanomedicines and Immunotherapy to Attack Cancer". Bilthoven.
     
   
Record changed: 2019-07-13

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for PRECIOUS project (2) (scaling-up immunomodulating nanomedicines for multimodal precision cancer immunotherapy) (EU, FP8, 201605–202104)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [iito] Made Without Love 650x80px




» top